# Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol

> **NCT06845254** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Xiyuan Hospital of China Academy of Chinese Medical Sciences** · enrollment: 400 (estimated)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)
- **DRUG:** placebo capsule

## Key facts

- **NCT ID:** NCT06845254
- **Lead sponsor:** Xiyuan Hospital of China Academy of Chinese Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2025-10-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06845254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06845254, "Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06845254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*